Patented Technology Offers Breakthrough Science
SALT LAKE CITY—January 30, 2014—Fluoresentric, Inc. today announced milestones in its plan to take molecular diagnostics testing to warp speed while reducing the cost of laboratory analysis. The successful polymerase chain reaction (PCR) assay design company is rapidly transforming to a start-up chemistry company positioned to monetize its disruptive XCR™ technology portfolio globally. Patented XCR™ is a novel nucleic acid amplification chemistry capable of tenfold faster results than PCR with superior resistance to classic PCR inhibitors. It works on existing PCR testing equipment, as well as on smaller, less costly technology under development.
“PCR testing in current use is four times faster than when DNA testing was made famous in the days of the OJ Simpson murder trial,” states Brian Caplin, Ph.D., chief science officer for Fluoresentric. “XCR™ raises that standard at ten times faster than existing PCR technology and protects lab investment by using existing equipment.”
The current standard for nucleic acid amplification requires 40 to 60 minutes, an unacceptable time for several critical testing areas, particularly at the Point of Care, where testing must be completed in less than 20 minutes to get a clinically actionable result. As a new approach to nucleic acid amplification testing (NAAT), XCR™ amplification and detection occurs in ~5 minutes with both DNA and RNA target nucleic acids. It eliminates amplification artifacts (e.g. primer-dimer) while dramatically reducing turnaround time, delivering a clinical result without compromise.
Recapitalized in 2014, the company is gathering an experienced management and advisory team while finalizing its Series B round of funding.
“Dr. Caplin’s pioneering work with Roche and PCR is well respected worldwide,” states William Olson, CEO for Fluoresentric. “We are now surrounding his disruptive XCR™ patents with the team and the funding needed to make a global impact on healthcare and molecular diagnostics at Point of Care.”
About Fluoresentric, Inc.
Fluoresentric Inc. is a start-up chemistry company positioned to monetize its XCR™ technology portfolio globally. Initially started as a custom PCR assay Design Company recruited by Roche to support their LightCycler® thermalcycler, the company has designed over 1,000 PCR assays. Fluoresentric scientists are internationally recognized experts in the field of Real Time Polymerase Chain Reaction (PCR). The company’s XCR™ technology is positioned to dramatically trim test times, reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing at Point of Care.
Help employers find you! Check out all the jobs and post your resume.
